Welcome to our dedicated page for NexGel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on NexGel stock.
NexGel, Inc (symbol: NXGL) specializes in the manufacture of advanced hydrogel solutions. The company's core business revolves around creating unique trans-dermal delivery systems initially developed and FDA-approved for the hospital wound care market. Today, NexGel has expanded its offerings to include consumer over-the-counter (OTC) products, prescription (Rx) applications, medical devices, and cosmetic products.
NexGel Inc is renowned for its high water content, electron beam cross-linked, aqueous polymer hydrogels. These gels are integral to various applications such as wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company's expertise lies in producing custom gels utilizing proprietary manufacturing technologies. The hydrogels and consumer products are created through a combination of proprietary and non-proprietary mixing, coating, and cross-linking technologies.
The company's recent achievements and current projects highlight its ongoing commitment to innovation and excellence in the hydrogel market. NexGel continually explores new partnerships and collaborations to enhance its product offerings and market reach.
For investors and stakeholders, it is important to note the company's strategic communications are managed by KCSA, with Valter Pinto serving as the Managing Director. NexGel’s financial condition and market performance are presented through regular updates, ensuring transparency and keeping investors well-informed.
For the latest developments, financial updates, and detailed information about NexGel, Inc, please refer to the following contact details:
Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications
Phone: 212.896.1254
Email: valter@kcsa.com
NEXGEL (NASDAQ: NXGL) has announced a $1,110,000 registered direct offering led by company insiders. The offering includes the sale of 444,000 shares of common stock and warrants to purchase up to 222,000 additional shares. The combined purchase price is $2.50 per share, with warrants exercisable at $4.25 per share for five years. Notably, NEXGEL insiders, including management and board members, participated in the offering and are subject to a six-month lock-up period. CEO Adam Levy stated that the capital will support operations and strengthen the balance sheet as the company approaches significant growth opportunities, particularly following the acquisition of Silly George and increased demand for its products.
NEXGEL (NASDAQ: NXGL) and Innovative Optics US dba Vanalay have initiated an IRB study to evaluate the efficacy of NEXGEL's hydrogel in eliminating harmful particles during laser hair removal. The 30-patient study, funded by Vanalay, aims to address concerns about surgical plume, a toxic byproduct of laser procedures. NEXGEL's high-water content hydrogel may offer a solution for absorbing and capturing plume, potentially improving treatment effectiveness and reducing pain. The study, conducted by plastic surgeons at the Florida Clinical Research Center, is expected to yield top-line data in Q4 2024. This collaboration could lead to a market solution addressing regulatory compliance and clinician health concerns in the laser aesthetics industry.
NEXGEL (NASDAQ: NXGL) announced preliminary unaudited revenue for Q2 2024 at $1.4 million, marking a 20% year-over-year and 10% sequential increase. The company also issued revenue guidance for Q3 and Q4 2024: $2.2 million and $2.6 million, respectively, indicating significant year-over-year growth of 83% and 140%. CEO Adam Levy highlighted the record Q2 revenue despite lower contributions from CG Converting and Packaging due to facility expansion. The growth in contract manufacturing, driven by new relationships with large global corporations, and strong consumer demand for products like Silly George's Pop-On Lash, has positioned the company to potentially achieve positive cash flow from operations in the latter half of 2024.
NEXGEL, a leading provider of medical and OTC products like hydrogels, announced a supply agreement with Cintas
Cintas, a top provider of corporate uniforms and safety products, will distribute SilverSeal, NEXGEL's hospital-grade hydrogel dressing for wounds and burns, to its customers in various sectors.
The first order is expected in Q4 2024. This partnership aims to enhance SilverSeal's brand awareness and generate revenue for NEXGEL.
CEO Adam Levy emphasized the significance of the partnership for both revenue and brand visibility.
NEXGEL has partnered with STADA Arzneimittel AG to launch Histasolv, a leading Diamine Oxidase (DAO) enzyme supplement, in North America. Histasolv, known as DAOSIN in Europe, generates over $10 million annually in Europe, treating histamine food intolerance. NEXGEL will start direct-to-consumer sales in Q3 2024. The product's unique formulation ensures high potency, addressing migraines, gut issues, and skin conditions caused by histamine intolerance. STADA, a top European healthcare company, aims to strengthen its North American presence through this partnership. Both companies express confidence in the collaborative potential and future expansion opportunities.
NEXGEL (NASDAQ: NXGL) has acquired Silly George, an international beauty brand specializing in eye and eyelash products, for $400,000 in cash, $200,000 in NEXGEL common stock, and a 4-year net profit earn out. Silly George, with a revenue run rate of approximately $2 million, offers a range of products including non-toxic eyelash extensions and lash serums, predominantly sold direct-to-consumer and on Amazon in the U.S., U.K., Australia, and the Netherlands. The acquisition is expected to add $2 million in annual revenue and provides operational synergies through marketing optimization and expense overlap. Silly George's strong social media presence and customer database will also offer cross-selling opportunities for NEXGEL's portfolio. CEO Adam Levy highlighted the acquisition as a strategic move towards profitability, leveraging synergies and expanding their product portfolio in the health and beauty sector.
NEXGEL (NASDAQ: NXGL) announced its financial results for Q1 2024, reporting a 104% YoY revenue increase to $1.27 million, driven by 58% growth in contract manufacturing and 178% in consumer branded products. The gross profit for Q1 2024 was $277,000, up from a loss of $57,000 in Q1 2023. However, the company reported a net loss of $905,000, up from $807,000 in the same period last year. NEXGEL is investing in significant growth opportunities, including expanding its Texas facility and launching products in Europe. The company ended the quarter with a cash balance of $2.4 million.
NEXGEL, Inc. will report its first quarter 2024 financial results on May 13th, followed by a conference call at 4:30 P.M. ET. The company is a leading provider of medical and over-the-counter products, including hydrogels for healthcare and consumer applications.
NEXGEL, Inc. will be presenting at the Aegis Capital Virtual Conference on May 9, 2024. The company specializes in medical and OTC products, such as hydrogels, for healthcare and consumer use. The CEO, Adam Levy, will be the speaker at the conference.
FAQ
What is the current stock price of NexGel (NXGL)?
What is the market cap of NexGel (NXGL)?
What does NexGel, Inc specialize in?
What are the primary applications of NexGel's products?
What is unique about NexGel's manufacturing technology?
Who handles investor relations for NexGel?
How did NexGel begin its journey in the hydrogel market?
What is the significance of NexGel’s hydrogels in consumer products?
How can one stay updated with NexGel's latest news and developments?
What financial information is available for NexGel investors?
Where can I find more detailed information about NexGel, Inc?
